Metabolic surgery in the treatment algorithm for type 2 diabetes
Vivian Fonseca, MD, shares insights on the new joint consensus statement from the 2nd Diabetes Surgery Summit
Vivian Fonseca, MD, on the FDA’s Canagliflozin Warning About Amputations
"It's important to evaluate the foot appropriately in all patients with diabetes."
Mayer B. Davidson, MD on Pioglitazone and Bladder Cancer
"It's time to resurrect pioglitazone."
Vivian Fonseca, MD, addresses the question of whether antibiotic exposure increases the risk for type 2 diabetes
"Until a more definitive answer is obtained, it seems prudent to advocate for the appropriate rather than indiscriminate use of antibiotics."
Ed Horton, MD, on EMPA-REG OUTCOME Results
"Reducing CVD outcomes requires a global approach—focusing on glucose alone is not enough."
Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths
"Landmark event in clinical trials for patients with type 2 diabetes."
Silvio Inzucchi, MD, on IMPROVE-IT Subanalysis: CV Benefits of Ezetimibe Exclusive to Subjects With Diabetes
"When one focuses on solely the diabetic cohort, the advantages of ezetimibe were large."
Silvio Inzucchi, MD, on TECOS Subanalysis: No Heart Failure Risk With Sitagliptin in High-Risk Type 2 Diabetes
"For now, we can continue to prescribe sitagliptin without any concerns for heart failure."
Vivian Fonseca, MD, on Results of ELIXA, the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist
"ELIXA results are reassuring and answer an important question for patients whose diabetes is challenging to control as they recover from a cardiovascular event."
Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor, Sitagliptin
"The finding of no difference in hospitalization for heart failure between the sitagliptin and placebo groups is somewhat reassuring and argues against the DPP-4 inhibitor class effect."
Silvio E. Inzucchi, MD, on Type 2 Diabetes Treatment Recommendations from ADA/EASD
"The emphasis remains on the individualization of treatment targets and strategies."
Silvio E. Inzucchi, MD, on Phentermine Plus Topiramate for Weight Loss in Type 2 Diabetes
"Weight loss remains a great challenge for our patients, especially those with diabetes."
Silvio E. Inzucchi, MD, on the Association Between Severe Hypoglycemia and Macrovascular Risk in Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study
"This paper adds to a growing body of literature demonstrating the higher cardiovascular risk of patients with type 2 diabetes and a history of severe hypoglycemia."
Silvio E. Inzucchi, MD, on the Impact of Lifestyle Interventions on Healthcare Services and Costs in Look AHEAD
"While intensive lifestyle changes to promote weight loss may not have any measurable effects on hard cardiovascular outcomes, with the adoption of a healthier lifestyle, healthcare costs can be substantially reduced."
Vivian A. Fonseca, MD, on Type 2 Diabetes Prevention in SEQUEL
"Weight loss alone may be an option to prevent type 2 diabetes."
Vivian A. Fonseca, MD, on Type 2 Diabetes Treatment Trends in the U.S.
"Clinicians could use these data to determine whether their own prescribing has changed in line with national trends."
Silvio E. Inzucchi MD, comments on SAVOR-TIMI 53
"Reassurance of the Overall Cardiovascular Safety of Saxagliptin and, One Might Infer, Other DPP-4 Inhibitors—But Heart Failure Signal Needs to Be Explored Further."
Vivian A. Fonseca, MD, on Data Exploring Whether a Diurnal Pattern to Insulin Action Exists in Type 1 Diabetes
"We need to redouble our efforts to personalize insulin therapy and keep it as flexible as possible."
Vivian A. Fonseca, MD, on the Basal Plus Trial: Is There an Optimal Insulin Strategy for Inpatient Glycemic Control?
"A 'basal plus regimen' may help clinicians to overcome hesitation about prescribing basal bolus insulin regimens."
NDEI.org Exclusive! ADVANCE, SOS, and VADT: Can Data from New Post-hoc Analyses of These Studies Change Practice?
Vivian Fonseca, MD, addresses the question of whether data from new post-hoc analyses of studies like ADVANCE, SOS, and VADT can change practice.
Silvio E. Inzucchi, MD, on the ADA/AGS Consensus Report on Diabetes in Older Adults
"Individualizing therapy, especially in our aging patients, is the only way to guarantee success."
Look AHEAD Trial Halted—Lifestyle Modifications Fail to Reduce CV Events in Patients With Diabetes
"Prevention of obesity and diabetes remains key."
Henry Ginsberg, MD, on a post-hoc analysis of ACCORD BP
"Interesting to note that the event rate of the composite endpoint did not rise with increasing obesity in the intensive therapy group but did with standard therapy."
Peter Libby, MD, on statins and diabetes risk in JUPITER
"Withholding statins from individuals at risk for or with diabetes, who meet current criteria, deprives them of a treatment with the potential of reducing heart attack, stroke, and death."
À la Moore’s Law in the Development of Antihyperglycemic Agents
"It is not at all clear that favorable effects of incretins on glycemic control will translate into long-term clinical benefit with respect to macrovascular disease."
NDEI.org Exclusive! The Effects of Insulin Glargine and Omega-3 Fatty Acids on Cardiovascular Death in Diabetes or Prediabetes in the ORIGIN trial
"These results may help us to educate our patients on the futility of adding over-the-counter medications like these supplements, in the hope of added benefit, in the absence of data supporting their use."
This content was not associated with funding via an educational grant or a promotional/commercial interest.